[(1R)-2-amino-1-methylethyl]carbamic acid 9H-fluoren-9-ylmethyl ester | 333743-52-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: [(1R)-2-amino-1-methylethyl]carbamic acid 9H-fluoren-9-ylmethyl ester
• 英文别名: [(1R)-2-amino-1-methylethyl]carbamic acid, 9H-fluoren-9-ylmethyl Ester；9H-fluoren-9-ylmethyl N-[(2R)-1-aminopropan-2-yl]carbamate
• CAS: 333743-52-5
• 化学式: C₁₈H₂₀N₂O₂
• 分子量: 296.369
• InChiKey: YZEFOFQSHAMXPE-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [(1R)-2-amino-1-methylethyl]carbamic acid 9H-fluoren-9-ylmethyl ester 、 对硝基苯基氯甲酸酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 (4-nitrophenyl) N-[(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propyl]carbamate
  参考文献：
  名称：

  Structure−Affinity Relationships of Glutamine Mimics Incorporated into Phosphopeptides Targeted to the SH2 Domain of Signal Transducer and Activator of Transcription 3

  摘要：

  In cancer cells, signal transducer and activator of transcription 3 (Stat3) participates in aberrant growth, survival, angiogenesis, and invasion signals and is a validated target for anticancer drug design. We are targeting its SH2 domain to prevent docking to cytokine and growth factor receptors and subsequent signaling. One of the important elements of the recognition sequence, pTyr-Xxx-Xxx-Gln, is glutamine. We incorporated novel Gin mimics into a lead peptide, pCinn-Leu-Pro-Gln-NHBn, and found that a linear, unconstrained side chain and carboxamide are necessary for high affinity, and the benzamide can be eliminated. Replacement of Gln-NHBn with (R)-4-aminopentanamide or 2-aminoethylurea produced inhibitors with equal or greater potency than that of the lead, as judged by fluorescence polarization (IC50 values were 110 and 130 nM, respectively). When Pro was replaced with cis-3,4-methanoproline, the glutamine mimic, (4R,5S)-4-amino-5-benzyloxyhexanamide resulted in an IC50 of 69 nM, the highest affinity Stat3 inhibitor reported to date.

  DOI：

  10.1021/jm901105k
• 作为产物：
  描述：

  [(1R)-2-amino-1-methyl-2-oxoethyl]carbamic acid 9H-fluoren-9-ylmethyl ester 在 dimethyl sulfide borane 、 甲醇 、 乙醚 、 水 、 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 以to give the subtitle compound (3.1 g)的产率得到[(1R)-2-amino-1-methylethyl]carbamic acid 9H-fluoren-9-ylmethyl ester
  参考文献：
  名称：

  Pteridine compounds for the treatment of psoriasis

  摘要：

  本发明提供了公式(I)的黄素化合物，以及其制备过程和中间体，包含它们的药物组合物以及它们在治疗中的应用。公式(I)中，A是公式(a)或(b)的基团。

  公开号：

  US20050171345A1

文献信息

• Novel thiazolo (4,5-D) pyrimidine compounds
  申请人：AstraZeneca UK Limited, a British corporation

  公开号：US20040224961A1

  公开（公告）日：2004-11-11

  The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof; processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. 1

  本发明提供式（I）的某些噻唑嘧啶化合物或其药学上可接受的盐或溶剂；用于它们的制备的过程和中间体，含有它们的制药组合物及其在治疗中的用途。
• Pteridine compounds for the treatment of psoriasis
  申请人：Bonnert Roger

  公开号：US20050171345A1

  公开（公告）日：2005-08-04

  The invention provides pteridine compounds of formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. Formula (I) in which A is a group of formula (a) or (b).

  本发明提供了公式(I)的黄素化合物，以及其制备过程和中间体，包含它们的药物组合物以及它们在治疗中的应用。公式(I)中，A是公式(a)或(b)的基团。
• Thiazolo(4,5-d)pyrimidine compounds
  申请人：AstraZeneca UK Limited

  公开号：US06790850B1

  公开（公告）日：2004-09-14

  The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof; processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的某些噻唑嘧啶化合物或其药学上可接受的盐或溶剂；用于它们的制备的过程和中间体，含有它们的制药组合物以及它们在治疗中的应用。
• NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS
  申请人：Willis Paul Andrew

  公开号：US20090281123A1

  公开（公告）日：2009-11-12

  The invention provides certain thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  该发明提供了式（I）的某些噻唑嘧啶化合物或其药学上可接受的盐或溶剂，用于制备它们的过程和中间体，含有它们的制药组合物以及它们在治疗中的应用。
• Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis
  申请人：AstraZeneca UK Limited

  公开号：EP1348709B1

  公开（公告）日：2008-01-16